Merit Medical (MMSI) Q2 2026 Earnings Call Transcript
Merit Medical Systems (MMSI) reported Q2 2026 revenue of $418.8 million, up 10% GAAP, and non-GAAP EPS of $1.19. Non-GAAP operating margin was 22.6% and free cash flow $51.9 million. The company raised 2026 revenue guidance to $1.631B-$1.643B and non-GAAP EPS to $4.25-$4.35, and guided Q3 revenue to $408M-$413M.
How this was made
The 30-second read
Why it matters
The key tradable update is the combination of a Q2 beat and raised full-year revenue and non-GAAP EPS guidance, alongside specific operational drivers (gross margin expansion, efficiencies, tariff refund) and forward-looking ranges for Q3.
Market read
Traders can update valuation and positioning based on raised 2026 guidance and the disclosed Q3 revenue and EPS ranges, while monitoring risks around tariffs and recall recapture.
What to watch
OEM growth depends on new agreements and restocking, and procedural solutions weakness (down 12% constant currency) could reassert pressure if divestiture effects or competitive dynamics worsen.
Background
Merit Medical Systems held its Q2 2026 earnings call, covering revenue/margin performance, product segment trends, and updated 2026 and Q3 guidance.
Ticker impact
Merit Medical reported Q2 2026 revenue of $418.8M, raised 2026 revenue guidance to $1.631B-$1.643B, and lifted non-GAAP EPS to $4.25-$4.35.
Moderately positive bias for the next few sessions as traders reprice 2026 EPS and margin trajectory, tempered by international trade cost uncertainty and recall recapture timing.
The article provides multiple fresh, decision-relevant datapoints: Q2 beat, raised full-year guidance, Q3 ranges, and specific drivers (gross margin expansion, tariff refund, recall resolution).
Market effects
Medical device peers may see read-across on vascular intervention, endoscopy, and oncology localization demand, especially if margin expansion is sustained.
U.S. outperformance (revenue $252M, up 11%) and Asia-Pacific growth (international $166.8M, up 7.3%) can influence regional demand expectations for device distributors.
Tariff uncertainty remains a cross-border cost risk, highlighted by management’s difficulty forecasting trade costs.
Counterpoint
Tariff refund ($6.9M) and one-time items can overstate underlying gross margin momentum, while recall recapture may lag and international trade costs are hard to forecast.
Key entities
- companyMerit Medical Systems
Reported Q2 2026 results and updated 2026 revenue and non-GAAP EPS guidance, plus Q3 2026 revenue and EPS ranges.
- executiveMartha Aronson
CEO who discussed competitive dynamics, oncology platform expansion, and ongoing M&A evaluation.
- executiveRaul Parra
CFO who attributed margin expansion to pricing discipline and manufacturing efficiencies and flagged tariff forecasting uncertainty.
